Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis

Abstract Background The management of diabetic foot osteomyelitis (DFO) is complex. The targeted use of adjuvant local antibiotics, in the form of biocomposite bone void filler, in DFO, can enhance patient outcomes while minimising the adverse effects associated with systemic antibiotic therapy and...

Full description

Saved in:
Bibliographic Details
Main Authors: Sara Metaoy, Iulia Rusu, Anand Pillai
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Clinical Diabetes and Endocrinology
Online Access:https://doi.org/10.1186/s40842-024-00200-w
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850133176428527616
author Sara Metaoy
Iulia Rusu
Anand Pillai
author_facet Sara Metaoy
Iulia Rusu
Anand Pillai
author_sort Sara Metaoy
collection DOAJ
description Abstract Background The management of diabetic foot osteomyelitis (DFO) is complex. The targeted use of adjuvant local antibiotics, in the form of biocomposite bone void filler, in DFO, can enhance patient outcomes while minimising the adverse effects associated with systemic antibiotic therapy and its shortcomings. Methods We reviewed a series of 105 consecutive patients who underwent surgical management for diabetic foot osteomyelitis. In the NLAB group, (no adjuvant local antibiotic use), 49 patients, received the current standard of care treatment with no use of adjunctive local antibiotic therapy. In group LAB, (adjuvant use of local antibiotics), 56 patients received additional adjuvant local antibiotic therapy. Patient outcomes were compared between both groups. Results Infection healing was demonstrated in 10 (20.41%) patients from group NLAB and 41 (73.21%) from group LAB (p < 0.0001). Persistence of infection with no evidence of wound healing, 6 months from surgery, was observed in 15 (30.61%) patients in group NLAB. Among the LAB group, only 4 (7.14%) patients demonstrated infection persistence (p = 0.00183). Reinfection was observed in 24 of 49 patients in group NLAB (49%) and in only 11 out of 56 patients in group LAB (20%) (p = 0.001466). 7 (6.67%) patients required major amputation with 6 (12.24%) belonging to group NLAB. Only 1 (1.78%) patient in group LAB underwent major amputation. A higher 5-year mortality rate was noted within patients in group NLAB, 27 (55.1%). The mortality rate in group LAB was (12.5%). Conclusion The adjuvant use of antibiotic loaded bio-composite bone void filler locally was associated with increased infection clearance rates regarding diabetic foot osteomyelitis when compared with the standard care of treatment while achieving lower rates of infection persistence and recurrence. It also has the potential to reduce amputation and mortality rates with further research.
format Article
id doaj-art-aab8cb9473ee4753bf004c977934fbbe
institution OA Journals
issn 2055-8260
language English
publishDate 2024-12-01
publisher BMC
record_format Article
series Clinical Diabetes and Endocrinology
spelling doaj-art-aab8cb9473ee4753bf004c977934fbbe2025-08-20T02:32:03ZengBMCClinical Diabetes and Endocrinology2055-82602024-12-011011610.1186/s40842-024-00200-wAdjuvant local antibiotic therapy in the management of diabetic foot osteomyelitisSara Metaoy0Iulia Rusu1Anand Pillai2University of ManchesterUniversity of ManchesterUniversity of ManchesterAbstract Background The management of diabetic foot osteomyelitis (DFO) is complex. The targeted use of adjuvant local antibiotics, in the form of biocomposite bone void filler, in DFO, can enhance patient outcomes while minimising the adverse effects associated with systemic antibiotic therapy and its shortcomings. Methods We reviewed a series of 105 consecutive patients who underwent surgical management for diabetic foot osteomyelitis. In the NLAB group, (no adjuvant local antibiotic use), 49 patients, received the current standard of care treatment with no use of adjunctive local antibiotic therapy. In group LAB, (adjuvant use of local antibiotics), 56 patients received additional adjuvant local antibiotic therapy. Patient outcomes were compared between both groups. Results Infection healing was demonstrated in 10 (20.41%) patients from group NLAB and 41 (73.21%) from group LAB (p < 0.0001). Persistence of infection with no evidence of wound healing, 6 months from surgery, was observed in 15 (30.61%) patients in group NLAB. Among the LAB group, only 4 (7.14%) patients demonstrated infection persistence (p = 0.00183). Reinfection was observed in 24 of 49 patients in group NLAB (49%) and in only 11 out of 56 patients in group LAB (20%) (p = 0.001466). 7 (6.67%) patients required major amputation with 6 (12.24%) belonging to group NLAB. Only 1 (1.78%) patient in group LAB underwent major amputation. A higher 5-year mortality rate was noted within patients in group NLAB, 27 (55.1%). The mortality rate in group LAB was (12.5%). Conclusion The adjuvant use of antibiotic loaded bio-composite bone void filler locally was associated with increased infection clearance rates regarding diabetic foot osteomyelitis when compared with the standard care of treatment while achieving lower rates of infection persistence and recurrence. It also has the potential to reduce amputation and mortality rates with further research.https://doi.org/10.1186/s40842-024-00200-w
spellingShingle Sara Metaoy
Iulia Rusu
Anand Pillai
Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis
Clinical Diabetes and Endocrinology
title Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis
title_full Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis
title_fullStr Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis
title_full_unstemmed Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis
title_short Adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis
title_sort adjuvant local antibiotic therapy in the management of diabetic foot osteomyelitis
url https://doi.org/10.1186/s40842-024-00200-w
work_keys_str_mv AT sarametaoy adjuvantlocalantibiotictherapyinthemanagementofdiabeticfootosteomyelitis
AT iuliarusu adjuvantlocalantibiotictherapyinthemanagementofdiabeticfootosteomyelitis
AT anandpillai adjuvantlocalantibiotictherapyinthemanagementofdiabeticfootosteomyelitis